



Esperion Therapeutics, Inc.
Investor Relations Department
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ESPR


Last Trade:	37.54
Trade Time:	4:00 PM ET May 25, 2018
Change:	-0.15 (-0.398%)
Day Range	36.88 - 38.07
52-Week Range	30.95 - 82.68
Volume	740,147

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 25, 2018

[Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

May 23, 2018

[Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint](#)

May 22, 2018

[Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference](#)

May 10, 2018

[Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference](#)

May 4, 2018

[Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference](#)

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Feb 20, 2018

[Annual Report \(10-K\)](#)

Apr 13, 2018

[Proxy Statement \(DEF 14A\)](#)

May 2, 2018

[Quarterly Report \(10-Q\)](#)

Nov 7, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)